Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brivanib alaninate + docetaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral (for Brivanib Alaninate), Intravenous (for Docetaxel)
01
Overview
**Brivanib alaninate + docetaxel** is an investigational combination therapy composed of brivanib alaninate, an oral small molecule tyrosine kinase inhibitor active against vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and fibroblast growth factor (FGF) receptors, and docetaxel, a cytotoxic antineoplastic agent that stabilizes microtubules and inhibits cell division. Brivanib targets tumor angiogenesis and proliferation, while docetaxel acts by disrupting microtubule function, leading to cell death in dividing cancer cells. This combination has been studied in advanced solid tumors, including gastrointestinal and hepatic cancers, primarily at the phase 1 trial level to establish safety, tolerability, and appropriate dosing[1][3][4][5][6].
- Brand names
- None known for the specific combination
- Other names
- None known for the specific combination
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)TUBB (Tubulin (alpha and beta subunits))FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on brivanib alaninate + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brivanib alaninate + docetaxel.